ADAMTS13 and cancer: A vWF:Ag level above the 75th percentile was associated with a 3.8-fold increased risk of developing DVT, and an ADAMTS-13 level below the 25th percentile was associated with an approximately 2.7-fold increased risk of developing DVT in cancer patients after chemotherapy.